Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AVI BioPharma has entered into an agreement with scientists at the Swedish medical university Karolinska Institutet for the identification of RNA-based therapeutic candidates for the treatment of Extensively Drug-Resistant Tuberculosis (XDR-TB).
Subscribe to our email newsletter
Under the agreement, both the parties are expected to investigate RNA-based drug candidates using AVI’s proprietary, intrinsically charge-neutral, phosphorodiamidate morpholino oligomer (PMO) based chemistry platform.
The intellectual property developed under the collaboration will be jointly owned.
However, AVI will retain rights to the therapeutic candidates employed in the collaboration and will hold hold an exclusive option to negotiate with the Karolinska Institutet to acquire its interest in that intellectual property.
AVI president and CEO Chris Garabedian said that this collaboration pairs AVI’s experience targeting bacterial and host factor genes using proprietary PMO-based chemistries with world scientific leaders in the research and treatment of XDR-TB.